Cornerstone Capital Management Holdings LLC. lessened its position in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 9.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 255,300 shares of the company’s stock after selling 27,900 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.56% of Amphastar Pharmaceuticals worth $4,911,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the business. Paloma Partners Management Co bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $197,000. Stone Ridge Asset Management LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $214,000. Driehaus Capital Management LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $229,000. Renaissance Technologies LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $227,000. Finally, Alliancebernstein L.P. increased its stake in Amphastar Pharmaceuticals by 148.9% in the fourth quarter. Alliancebernstein L.P. now owns 113,520 shares of the company’s stock valued at $2,184,000 after purchasing an additional 67,920 shares in the last quarter. 44.82% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Several brokerages have recently issued reports on AMPH. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Needham & Company LLC reissued a “buy” rating and set a $24.00 price objective (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BMO Capital Markets reissued a “market perform” rating and set a $19.00 price objective (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $21.33.

In related news, CFO William J. Peters sold 19,801 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total value of $398,000.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jason B. Shandell sold 18,627 shares of the firm’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $19.42, for a total transaction of $361,736.34. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,387 shares of company stock valued at $1,659,763. 11.10% of the stock is owned by insiders.

Shares of Amphastar Pharmaceuticals stock opened at $19.51 on Thursday. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12. Amphastar Pharmaceuticals Inc has a 12-month low of $13.15 and a 12-month high of $20.45. The stock has a market cap of $901.06, a price-to-earnings ratio of 62.71, a PEG ratio of 1.38 and a beta of 1.46.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, March 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The company had revenue of $60.40 million during the quarter, compared to the consensus estimate of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.01 earnings per share. research analysts expect that Amphastar Pharmaceuticals Inc will post 0.63 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/amphastar-pharmaceuticals-inc-amph-holdings-reduced-by-cornerstone-capital-management-holdings-llc/1955598.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.